Search results
Results from the WOW.Com Content Network
While prognosis is highly variable and dependent on various factors including these mutations, the average 5-year relative survival is 86.1%. [85] Telomere length has been suggested to be a valuable prognostic indicator of survival. [86] In addition, a person's sex has been found to have an impact on CLL prognosis and treatment efficacy.
CLL/SLL is the most common adult leukemia in Western countries, accounting for 1.2% of the new cancers diagnosed each year in the United States. It usually occurs in older adults (median age at diagnosis 70) and follows an indolent course over many years. [11] About 1-10% of CLL/SLLs develop a Richter's transformation at a rate of 0.5–1% per ...
It is treated with imatinib (Gleevec in United States, Glivec in Europe) or other drugs. [20] The five-year survival rate is 90%. [21] [22] One subtype is chronic myelomonocytic leukemia. Hairy cell leukemia (HCL) is sometimes considered a subset of chronic lymphocytic leukemia, but does not fit neatly into this category. About 80% of affected ...
The 5-year survival rate for children with leukemia is 83.6% in the USA. This means that 83.6% of children diagnosed with leukemia live for 5 years or more after their diagnosis. This is greatly improved from a 5-year survival rate of 36.5% in 1975. The improvement is largely attributed to advances in therapy, particularly therapy for ALL.
The lymphocyte subtypes are B-cells that share certain features with the abnormal clones of lymphocytes that circulate in chronic lymphocytic leukemia/small lymphocyte lymphoma (CLL/SLL) or, less frequently, other types of B-cell malignancies. Some individuals with these circulating B-cells develop CLL/SLL or the lymphoma types indicated by ...
Deletion of 13q14 (del 13q14) is the most common abnormality in CLL with roughly 50% of patients with cells containing this defect. When del 13q14 is seen in isolation, patients have the best prognosis and most will live many years, even decades, without the need for therapy.
CLL is a cancer that develops from overproduction of B cells in the bone marrow. In people with CLL, higher levels of ZAP-70 confers a worse prognosis; CLL patients that are positive for the marker ZAP-70 have an average survival of 8 years, whereas those that are negative for ZAP-70 have an average survival of more than 25 years.
In a study based in the US, the average age of diagnosis was 66.5 years [3] whereas in a French study the median age at diagnosis was 59 years (with an age range of 12–87 years old). [4] In the French study, only 26% of patients were younger than 50 years which suggests that this disorder is associated with older age at diagnosis. [ 4 ]